Recruiting
Phase 3

MK-1084 & Pembrolizumab

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06345729

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MK-1084

Placebo

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information